Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials-Reference-Cited by-同舟云学术

Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials

Published:2019-01 Issue: Volume:106 Page:1-11
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Nie Run-Cong^ORCID,Chen Fo-Ping,Yuan Shu-Qiang,Luo Ying-Shan,Chen Shi,Chen Yong-Ming^ORCID,Chen Xiao-Jiang,Chen Ying-Bo,Li Yuan-Fang,Zhou Zhi-Wei

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference68 articles.

1. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008

2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Canc,2012

3. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018

4. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010

5. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy;npj Systems Biology and Applications;2024-08-14

2. Predict progression free survival and overall survival using objective response rate for anti—PD1/PDL1 therapy development;BMC Cancer;2024-07-29

3. Predict progression free survival and overall survival using objective response rate for anti - PD1 / PDL1 therapy development;2024-05-14

4. Hybridizing mechanistic mathematical modeling with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy;2024-03-29

5. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study;Frontiers in Oncology;2024-02-12